Erbitux 5 mg/mL Injection (Cetuximab) — Targeted EGFR Cancer Therapy (1 Vial) Erbitux 5 mg/mL Injection contains cetuximab, a targeted monoclonal antibody used in the management of certain advanced cancers that express the epidermal growth factor receptor (EGFR), including metastatic colorectal cancer (wild-type RAS) and squamous cell carcinoma of the head and neck. Delivered as an intravenous infusion by trained healthcare professionals in oncology centers, Erbitux works by attaching to EGFR on tumor cells, blocking growth signals and enhancing the effectiveness of chemotherapy and radiotherapy. Due to the risk of infusion reactions, skin toxicities, and electrolyte imbalance, Erbitux treatment requires careful clinical supervision and regular blood tests, especially for magnesium levels. Available in Pakistan from licensed oncology pharmacies in a 5 mg/mL strength (commonly 100 mg/20 mL vial) with prescription support, Erbitux plays a vital role in modern targeted cancer therapy where appropriate genetic and clinical profiling has been conducted